Zynex, Inc.
Zynex, Inc. (ZYXI) Stock Competitors & Peer Comparison
See (ZYXI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZYXI | $2.49 | +0.40% | 75.3M | -10.38 | -$0.24 | N/A |
| MCK | $714.92 | +0.39% | 89.3B | 27.80 | $25.71 | +0.40% |
| COR | $291.80 | +0.70% | 56.6B | 33.77 | $8.64 | +0.74% |
| CAH | $157.90 | +0.32% | 37.7B | 24.72 | $6.39 | +1.29% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $69.58 | -0.67% | 8.5B | 21.68 | $3.21 | N/A |
| PBH | $75.13 | +0.64% | 3.7B | 17.52 | $4.29 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +0.83% |
| GRDN | $20.48 | +0.74% | 1.3B | -12.86 | -$1.59 | N/A |
| OMI | $7.11 | -4.63% | 545.5M | -1.50 | -$4.76 | N/A |
Stock Comparison
ZYXI vs MCK Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, MCK has a market cap of 89.3B. Regarding current trading prices, ZYXI is priced at $2.49, while MCK trades at $714.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas MCK's P/E ratio is 27.80. In terms of profitability, ZYXI's ROE is -0.24%, compared to MCK's ROE of -1.33%. Regarding short-term risk, ZYXI is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check MCK's competition here
ZYXI vs COR Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, COR has a market cap of 56.6B. Regarding current trading prices, ZYXI is priced at $2.49, while COR trades at $291.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas COR's P/E ratio is 33.77. In terms of profitability, ZYXI's ROE is -0.24%, compared to COR's ROE of +2.41%. Regarding short-term risk, ZYXI is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check COR's competition here
ZYXI vs CAH Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, CAH has a market cap of 37.7B. Regarding current trading prices, ZYXI is priced at $2.49, while CAH trades at $157.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas CAH's P/E ratio is 24.72. In terms of profitability, ZYXI's ROE is -0.24%, compared to CAH's ROE of -0.50%. Regarding short-term risk, ZYXI is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check CAH's competition here
ZYXI vs ABC Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, ZYXI is priced at $2.49, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas ABC's P/E ratio is 21.92. In terms of profitability, ZYXI's ROE is -0.24%, compared to ABC's ROE of +2.52%. Regarding short-term risk, ZYXI is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check ABC's competition here
ZYXI vs HSIC Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, HSIC has a market cap of 8.5B. Regarding current trading prices, ZYXI is priced at $2.49, while HSIC trades at $69.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas HSIC's P/E ratio is 21.68. In terms of profitability, ZYXI's ROE is -0.24%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, ZYXI is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check HSIC's competition here
ZYXI vs PBH Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, PBH has a market cap of 3.7B. Regarding current trading prices, ZYXI is priced at $2.49, while PBH trades at $75.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas PBH's P/E ratio is 17.52. In terms of profitability, ZYXI's ROE is -0.24%, compared to PBH's ROE of +0.12%. Regarding short-term risk, ZYXI is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check PBH's competition here
ZYXI vs PDCO Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, ZYXI is priced at $2.49, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas PDCO's P/E ratio is 20.48. In terms of profitability, ZYXI's ROE is -0.24%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, ZYXI is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check PDCO's competition here
ZYXI vs GRDN Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, ZYXI is priced at $2.49, while GRDN trades at $20.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas GRDN's P/E ratio is -12.86. In terms of profitability, ZYXI's ROE is -0.24%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, ZYXI is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check GRDN's competition here
ZYXI vs OMI Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, OMI has a market cap of 545.5M. Regarding current trading prices, ZYXI is priced at $2.49, while OMI trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas OMI's P/E ratio is -1.50. In terms of profitability, ZYXI's ROE is -0.24%, compared to OMI's ROE of -0.51%. Regarding short-term risk, ZYXI is more volatile compared to OMI. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check OMI's competition here
ZYXI vs WGRX Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, WGRX has a market cap of 68.6M. Regarding current trading prices, ZYXI is priced at $2.49, while WGRX trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas WGRX's P/E ratio is -1.18. In terms of profitability, ZYXI's ROE is -0.24%, compared to WGRX's ROE of -7.42%. Regarding short-term risk, ZYXI is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check WGRX's competition here
ZYXI vs GEG Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, GEG has a market cap of 58.1M. Regarding current trading prices, ZYXI is priced at $2.49, while GEG trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas GEG's P/E ratio is -41.60. In terms of profitability, ZYXI's ROE is -0.24%, compared to GEG's ROE of -0.02%. Regarding short-term risk, ZYXI is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check GEG's competition here
ZYXI vs HX Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, ZYXI is priced at $2.49, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas HX's P/E ratio is -1.84. In terms of profitability, ZYXI's ROE is -0.24%, compared to HX's ROE of -0.13%. Regarding short-term risk, ZYXI is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check HX's competition here
ZYXI vs RDGT Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, RDGT has a market cap of 6.6M. Regarding current trading prices, ZYXI is priced at $2.49, while RDGT trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas RDGT's P/E ratio is -4.31. In terms of profitability, ZYXI's ROE is -0.24%, compared to RDGT's ROE of -0.20%. Regarding short-term risk, ZYXI is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for ZYXI.Check RDGT's competition here
ZYXI vs CVET Comparison July 2025
ZYXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYXI stands at 75.3M. In comparison, CVET has a market cap of 0. Regarding current trading prices, ZYXI is priced at $2.49, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYXI currently has a P/E ratio of -10.38, whereas CVET's P/E ratio is -69.97. In terms of profitability, ZYXI's ROE is -0.24%, compared to CVET's ROE of -0.06%. Regarding short-term risk, ZYXI is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for ZYXI.Check CVET's competition here